These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 38290791)

  • 21. XK469, a topo IIbeta inhibitor, induces apoptosis in Waldenstrom's macroglobulinemia through multiple pathways.
    Mensah-Osman E; Al-Katib A; Dandashi M; Mohammad R
    Int J Oncol; 2003 Dec; 23(6):1637-44. PubMed ID: 14612935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effects of doxorubicin and a doxorubicin analog, 13-deoxy, 5-iminodoxorubicin (GPX-150), on human topoisomerase IIβ activity and cardiac function in a chronic rabbit model.
    Frank NE; Cusack BJ; Talley TT; Walsh GM; Olson RD
    Invest New Drugs; 2016 Dec; 34(6):693-700. PubMed ID: 27581956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid (XK469) inhibition of topoisomerase IIbeta is not sufficient for therapeutic response in human Waldenstrom's macroglobulinemia xenograft model.
    Mensah-Osman EJ; Al-Katib AM; Dandashi MH; Mohammad RM
    Mol Cancer Ther; 2002 Dec; 1(14):1315-20. PubMed ID: 12516964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism.
    Cusack BJ; Gambliel H; Musser B; Hadjokas N; Shadle SE; Charlier H; Olson RD
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):517-26. PubMed ID: 16555089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. XK469, a selective topoisomerase IIbeta poison.
    Gao H; Huang KC; Yamasaki EF; Chan KK; Chohan L; Snapka RM
    Proc Natl Acad Sci U S A; 1999 Oct; 96(21):12168-73. PubMed ID: 10518594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Doxorubicin-induced cardiotoxicity is maturation dependent due to the shift from topoisomerase IIα to IIβ in human stem cell derived cardiomyocytes.
    Cui N; Wu F; Lu WJ; Bai R; Ke B; Liu T; Li L; Lan F; Cui M
    J Cell Mol Med; 2019 Jul; 23(7):4627-4639. PubMed ID: 31106979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 2-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid (XK469), an inhibitor of topoisomerase (Topo) IIbeta, up-regulates Topo IIalpha and enhances Topo IIalpha-mediated cytotoxicity.
    Mensah-Osman EJ; Al-Katib AM; Wu HY; Osman NI; Mohammad RM
    Mol Cancer Ther; 2002 Dec; 1(14):1321-6. PubMed ID: 12516965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topoisomerases and Anthracyclines: Recent Advances and Perspectives in Anticancer Therapy and Prevention of Cardiotoxicity.
    Mordente A; Meucci E; Martorana GE; Tavian D; Silvestrini A
    Curr Med Chem; 2017; 24(15):1607-1626. PubMed ID: 27978799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
    Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
    Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits.
    Jirkovský E; Lenčová-Popelová O; Hroch M; Adamcová M; Mazurová Y; Vávrová J; Mičuda S; Šimůnek T; Geršl V; Štěrba M
    Toxicology; 2013 Sep; 311(3):191-204. PubMed ID: 23831762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA sequence specificity for topoisomerase II poisoning by the quinoxaline anticancer drugs XK469 and CQS.
    Gao H; Yamasaki EF; Chan KK; Shen LL; Snapka RM
    Mol Pharmacol; 2003 Jun; 63(6):1382-8. PubMed ID: 12761349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.
    Hasinoff BB; Wu X; Patel D; Kanagasabai R; Karmahapatra S; Yalowich JC
    J Pharmacol Exp Ther; 2016 Feb; 356(2):397-409. PubMed ID: 26660439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of anthracycline extravasation with dexrazoxane.
    Langer SW; Sehested M; Jensen PB
    Clin Cancer Res; 2000 Sep; 6(9):3680-6. PubMed ID: 10999761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II.
    Hasinoff BB; Kuschak TI; Creighton AM; Fattman CL; Allan WP; Thampatty P; Yalowich JC
    Biochem Pharmacol; 1997 Jun; 53(12):1843-53. PubMed ID: 9256159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thioredoxin Decreases Anthracycline Cardiotoxicity, But Sensitizes Cancer Cell Apoptosis.
    Das KC; Muniyappa H; Kundumani-Sridharan V; Subramani J
    Cardiovasc Toxicol; 2021 Feb; 21(2):142-151. PubMed ID: 32880787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological strategies to reduce anthracycline-associated cardiotoxicity in cancer patients.
    Stansfeld A; Radia U; Goggin C; Mahalingam P; Benson C; Napolitano A; Jones RL; Rosen SD; Karavasilis V
    Expert Opin Pharmacother; 2022 Oct; 23(14):1641-1650. PubMed ID: 36102190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Lack of Synergy between Carvedilol and the Preventive Effect of Dexrazoxane in the Model of Chronic Anthracycline-Induced Cardiomyopathy.
    Szponar J; Ciechanski E; Ostrowska-Lesko M; Gorska A; Tchorz M; Dabrowska A; Dudka J; Murias M; Kowalczyk M; Korga-Plewko A; Mandziuk S
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373350
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Pokorna Z; Jirkovsky E; Hlavackova M; Jansova H; Jirkovska A; Lencova-Popelova O; Brazdova P; Kubes J; Sotakova-Kasparova D; Mazurova Y; Adamcova M; Vostatkova L; Holzerova K; Kolar F; Simunek T; Sterba M
    Clin Sci (Lond); 2019 Aug; 133(16):1827-1844. PubMed ID: 31409729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo.
    Popelová O; Sterba M; Simůnek T; Mazurová Y; Guncová I; Hroch M; Adamcová M; Gersl V
    J Pharmacol Exp Ther; 2008 Jul; 326(1):259-69. PubMed ID: 18434588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro.
    Fortin MC; LaCroix AS; Grammatopoulos TN; Tan L; Wang Q; Manca D
    Sci Rep; 2023 Nov; 13(1):21054. PubMed ID: 38030645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.